CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Calypte Biomedical Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Calypte Biomedical Corporation
15875 SW 72nd Ave
Phone: 503-726-2227p:503-726-2227 Portland, OR  97224  United States Ticker: CBMC CBMC
On 4/6/2015, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Calypte Biomedical Corporation for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Calypte Biomedical Corporation develops, manufactures and distributes in-vitro diagnostic tests for the diagnosis of Human Immunodeficiency Virus (HIV) infection. The Company focuses on the development and commercialization of its Aware HIV-1/2 rapid tests. It has completed field trials and product evaluations of Aware HIV-1/2 OMT (oral fluid) rapid test. The Company has regulatory approvals in Russia, India, China, Africa, Southeast Asia and the Middle East. The Company markets its products through distributors in South Africa and the United Arab Emirates (U.A.E.). The Company also manufactures and sells HIV-1 BED Incidence EIA test, an Aware BED Incidence Test, through an arrangement with the United States Centers for Disease Control and Prevention (the CDC). The Company’s product line includes its Aware line of tests, its Aware HIV-1 BED Incidence test and its Aware Messenger specimen collection device

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201212/31/2012YesYes--Yes

Industries
SIC Code Description
3826 Laboratory analytical instruments
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer AdelKaras 67 4/24/2012 5/8/2007
Chief Financial Officer, Secretary, Director KartlosEdilashvili 38 4/24/2012 2/4/2010
Independent Director TareqAl Yousefi 49 9/24/2009 9/24/2009

Business Names
Business Name
Calypte Biomedical Corporation
Calypte, Inc.
CBMC
HIV

General Information
Number of Employees: 4 (As of 12/31/2011)
Outstanding Shares: 700,168,157 (As of 6/24/2014)
Shareholders: 296
Stock Exchange: OTC
Federal Tax Id: 061226727
Fax Number: 503-601-6299


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023